Takemasa Tsuji to Neoplasms
This is a "connection" page, showing publications Takemasa Tsuji has written about Neoplasms.
Connection Strength
0.699
-
Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy. Cancer Immunol Res. 2018 05; 6(5):594-604.
Score: 0.221
-
Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood. 2005 Jul 15; 106(2):470-6.
Score: 0.090
-
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 Nov; 623(7989):1034-1043.
Score: 0.082
-
Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans. Cancer Res Commun. 2023 11 08; 3(11):2256-2267.
Score: 0.082
-
Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2881-2898.
Score: 0.073
-
Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res. 2014 Apr; 2(4):341-50.
Score: 0.041
-
Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clin Cancer Res. 2012 Oct 01; 18(19):5449-59.
Score: 0.037
-
The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004 Sep; 95(9):697-703.
Score: 0.022
-
Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res. 2004 Feb 15; 64(4):1490-5.
Score: 0.021
-
Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci. 2003 Oct; 94(10):924-8.
Score: 0.020
-
Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes. Eur J Immunol. 2013 Apr; 43(4):989-1000.
Score: 0.010